Identification of Methylation-Related Genes and Epigenetic Mechanism in CMS4 Colorectal Cancer

Strategic Insights -

Scientists at the Affiliated Hospital of Nantong University, Jiangsu, People's Republic of China, have conducted a study on the molecular characteristics of Consensus Molecular Subtype 4 (CMS4) of colorectal cancer (CRC). According to their research, CMS4 CRC is characterized by TGF-b activation and is often accompanied by metastasis and recurrence. To gain insights into the underlying mechanisms, researchers investigated methylation sites in CMS4 CRC and explored the role of SLAMF6 in CRC.

Key Takeaways:

  • The study identified 726 differentially methylated sites between CMS4 and CMS1-3 subtypes.
  • Random forest and LASSO regression analyses pinpointed significant methylation sites, and Kaplan Meier analysis identified prognosis-related sites.
  • The study highlighted the mechanistic role of SLAMF6 in CRC, involving TGF-b/SMAD3/DNMT1 pathway.
  • Researchers observed a potential target for CRC prognosis and immunotherapy using 5-Aza and PD-L1 antibody in tumor-bearing mice.
  • The research concluded that the TGF-b/SMAD3/DNMT1 pathway regulates SLAMF6 methylation, suggesting a novel epigenetic mechanism in CMS4 CRC.

Statistics:

  • 726 differentially methylated sites were detected between CMS4 and CMS1-3 subtypes.
  • Significant methylation sites were identified using random forest and LASSO regression analyses.
  • Kaplan Meier analysis revealed prognosis-related sites, highlighting the significance of methylation in CMS4 CRC.
  • 5-Aza, a methyltransferase inhibitor, and PD-L1 antibody demonstrated anti-tumor effects in tumor-bearing mice.

Sources:

  • NewsRx. Research from Affiliated Hospital of Nantong University Yields New Findings on Colon Cancer. Cancer Weekly. October 14, 2025; p 3798.
  • Yang, J., et al. Identification of methylation-related genes and the potential regulatory mechanism of SLAMF6 in CMS4 colorectal cancer. Clinical Epigenetics, 2025;17(1):166.